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Aim: Two oestrogen receptors (ERs) have been identified to date—the “classic” ERα and the more
recently described ERβ. Although much is known about ERα at the mRNA and protein levels, our
knowledge of the expression and distribution of ERβ protein is much more limited. The aim of this study
was to compare the cellular distribution of ERα and ERβ in normal human mammary gland.
Methods: Formalin fixed, paraffin wax embedded material was obtained from reduction
mammoplasty specimens, normal tissue adjacent to breast tumour, or fibroadenoma. Sections were
immunohistochemically stained for ERα, ERβ, and the progesterone receptor. The staining pattern for
each antibody was evaluated and compared.
Results: ERα was restricted to the cell nuclei of epithelial cells lining ducts and lobules. Although ERβ
was also seen in these cells, additional strong staining was detected specifically in the cell nuclei of
myoepithelial cells. Occasional staining was seen in surrounding stromal and endothelial cell nuclei
and in lymphocytes.
Conclusions: ER subtypes have distinct distribution patterns in the normal mammary gland. The wide-
spread distribution of ERβ suggests that it may be the dominant ER in the mammary gland where it may
be acting as a natural suppressor.
Towards the end of the last century, a second oestrogenreceptor (ER) was identified. To distinguish it from theoriginal receptor, now re-christened ERα, the new recep-
tor was called ERβ.1 2 ERs are ligand activated transcription
factors, which mediate the effect of oestrogens in steroid tar-
get tissues. The genes encoding the two types of receptor are
located on different chromosomes: ERβ has been mapped to
chromosome 14q22–24,3 whereas ERα is located on chromo-
some 6q25.1.4 Although they are the product of independent
genes, they share homology at the DNA and ligand binding
domains (96% and 58%, respectively2). Both receptor subtypes
bind oestrogens with a similar affinity and activate the
expression of reporter genes containing oestrogen response
elements in an oestrogen dependent manner.5
Oestrogens are necessary for the development and matura-
tion of the mammary gland. However, immunohistochemical
analysis of breast tissue from premenopausal women has esti-
mated that less than 20% of luminal epithelial cells express
Erα.6–8 Curiously, double immunolabelling experiments in
both human and murine mammary gland have shown that
cells that are immunopositive for ERα very rarely undergo
proliferation, as determined by the lack of expression of the
cell cycle associated antigens Ki-67 and proliferative cell
nuclear antigen, or failure to incorporate 3H-thymidine.7–9 It
has been hypothesised that the lack of proliferation seen in
ERα positive cells may indicate a hierarchical organisation,
whereby the proliferation of ERα negative cells is under the
control of paracrine factors released from their ERα positive
counterparts.8 However, the discovery of ERβ opens up the
possibility that cells originally considered ERα negative may
in fact be expressing ERβ. The presence of ERβ has been dem-
onstrated by reverse transcription polymerase reaction (RT-
PCR) in the normal mammary gland, where it was frequently
detected.10 11 This was in contrast to breast tumours where the
expression of ERβ is usually seen only in combination with
ERα.10 12 However, RT-PCR is limited because it cannot provide
information on cellular distribution patterns. Therefore, the
aim of our study was to evaluate the pattern of expression and
distribution of both ER subtypes in archival, paraffin wax
embedded, normal human mammary gland and to correlate
this with the expression of the ER regulated progesterone
receptor (PR).
“Both receptor subtypes bind oestrogens with a similar
affinity and activate the expression of reporter genes
containing oestrogen response elements in an oestrogen
dependent manner”
METHODS
With approval from the local ethics committee, archival paraf-
fin wax embedded material from normal breast adjacent to
tumours (n = 65), reduction mammoplasty material
(n = 30), or fibroadenoma (n = 2) was obtained. Serial
sections (4–5 µm thick) were mounted on to superfrost plus
slides (BDH, Poole, Dorset, UK), dewaxed in xylene, and rehy-
drated through graded alcohols. To unmask antigenic sites,
slides were immersed in 1mM citrate buffer, pH 6, and micro-
waved at full power (600 W) for 27 minutes for ERα and ERβ,
and 10 minutes for PR. After cooling, sections were then incu-
bated with the relevant monoclonal antibodies. For ERα, the
monoclonal antibody 1D5 (Dako, High Wycombe, UK) was
applied at a dilution of 1/50 for one hour at room temperature.
For ERβ, the monoclonal antibody 14C8 (Abcam, Cambridge,
UK) was applied at a dilution of 5 µg/ml overnight at 4°C. Vali-
dation of this antibody has previously been published by our
group.12 The antibody was affinity purified and raised by
immunising mice with a recombinant protein encoding 1–153
amino acids of the human ERβ sequence. According to the
manufacturers, there is no crossreactivity of 14C8 with human
ERα or ID5 with human ERβ. For PR, the monoclonal
antibody PgR636 (Dako) was used at a 1/50 dilution for one
hour at room temperature. After incubation with the
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appropriate biotinylated secondary antibody (Dako anti-
mouse; 1/200 dilution) for 30 minutes at room temperature,
then incubation with streptavidin ABC kit (Dako), the ER and
PR proteins were visualised with 3,3′-diaminobenzidine (Vec-
tor, Peterborough, UK). Negative controls included the
omission of the primary antibody or incubation with the
appropriate blocking peptide. Sections were lightly counter-
stained with haematoxylin, dehydrated, and coverslipped.
Slides were scored using a system involving the assessment of
staining intensity and percentage positivity,which generated a
numerical score of 0 to 8.13 A score of > 2 was classified as
positive. Staining was scored independently by two authors
Figure 1 (A) Expression of oestrogen receptor α (ERα) in normal mammary gland. Staining is restricted to the epithelial cells lining the breast
ducts (arrows). (B) Serial section of (A) but stained with a monoclonal antibody directed against ERβ. In addition to staining the ductal
epithelium (D), ERβ immunoreactivity is also seen in myoepithelial cells (M) and scattered periductal stromal fibroblasts (F). (C) Breast lobule
showing ERβ immunoreactivity in epithelial cells (E), intralobular fibroblasts (F), and in endothelial cells lining a blood vessel (V). (D)
Progesterone receptor immunoreactivity in the nuclei of normal breast epithelium (arrow).
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(GPS, PJC). Representative images were captured using a
Nikon light microscope attached to a computer equipped with
Lucia software (version 4.51).
RESULTS
Using serial sections, the expression and distribution of ERα
and ERβ were analysed and compared. In accordance with
previous reports, ERα was restricted to the cell nuclei of lumi-
nal epithelial cells lining ducts and lobules (fig 1A). However,
a much more widespread pattern of staining was seen with
ERβ (fig 1B). As with ERα, this receptor was also seen in the
nuclei of the same epithelial cells lining breast ducts and lob-
ules (fig 1B).However, additional strong staining was detected
specifically in the cell nuclei of myoepithelial cells (fig 1B).
Weak to moderate staining was seen in some intralobular
stromal cell nuclei, in nuclei of endothelial cells lining blood
vessels (fig 1C), and in lymphocytes. Whereas the expression
of ERα and ERβ tended to be uniform across a given section, a
more patchy distribution pattern was seen for PR, with weak
to moderate staining. PR was specifically localised to epithelial
cells (fig 1D), and although the coexpression of PR and ERα
and ERβ was seen in the same tissue section, it was not always
in the same cells.
In general, ERβ immunoreactivity was much stronger than
that of ERα, and the staining pattern was identical in breast
reduction specimens and in normal tissue adjacent to
tumours. In addition, the staining pattern and intensity for
ERβ did not appear to be affected by patient age. In all cases,
specific staining was abolished in negative controls.
DISCUSSION
We have shown the differential expression of the two ER
subtypes—ERα and ERβ—in normal human mammary
gland, with much more widespread expression of ERβ
compared with ERα.
The distribution patterns of each receptor were distinct.
Whereas ERα was restricted to the cell nuclei of epithelial
cells, a striking observation was the strong expression of ERβ
in the nuclei of myoepithelial cells. The presence of ERβ in
these cells may provide clues as to the function of this recep-
tor subtype in the mammary gland. The myoepithelium forms
a natural barrier separating proliferating epithelial cells from
the basement membrane and the underlying stroma. Myoepi-
thelial cells rarely undergo transformation and there is
experimental evidence that they may act as natural tumour
suppressors.14 In the mammary gland, loss of ERβ in the tran-
sition from benign lesion to carcinoma in situ has recently
been reported,15 16 prompting the proposal that ERβ may have
a role as a tumour suppressor.15 Strong, specific expression of
ERβ in the myoepithelium may strengthen this hypothesis,
where it may be fulfilling a protective function. Further
evidence in support of this is provided by Taylor and
Al-Azzawi,17 who described increased ERβ immunoreactivity
in the glands of normal resting breast tissue compared with
proliferative breast tissue.
In gene knockout studies, the presence of ERα but not ERβ
is necessary for the development of the mouse mammary
gland.18 Therefore, ERβ may be acting as an antagonist of ERα
and removing its antagonistic effect may be akin to “removing
a brake”. Thus, by removing ERβ the suppressive effect of the
receptor is lost. Alternatively, the putative suppressive effects
of ERβ may be dictated by the downstream signalling
pathway. Both ER subtypes can signal via classic oestrogen
response elements or via AP-1 enhancers.19 The downstream
effects of signalling through AP-1 are both receptor and ligand
specific. Whereas ERα–17β-estradiol complexes activate gene
transcription, the reverse is true for ERβ–17β-estradiol
complexes.20 Thus, if signalling is mediated through AP-1, an
inhibitory effect of ERβ might be expected.
ERβ was also observed in lymphocytes, stromal cells, and
endothelial cells. It has long been known that oestrogens have
important effects on the immune system and to this end ERβ
expression in lymphocytes has previously been reported.3 We
and others have reported stromal immunoreactivity for ERβ in
the mammary gland,11 16 17 and this has also been noted in
colon21 and prostate.22 In the endothelium,where it plays a role
in vascular remodelling,23 24 ERβ is believed to be the dominant
receptor subtype. Despite these observations, the functional
importance of ERβ in non-epithelial cells is unclear, although
it may be fulfilling a paracrine role. Future studies are required
to investigate this question.
“Myoepithelial cells rarely undergo transformation and
there is experimental evidence that they may act as natu-
ral tumour suppressors”
In the mouse mammary gland, ERβ is expressed by 60–70%
of epithelial cells, irrespective of the stage of breast
development.9 In our study, we did not attempt to correlate
ERβ expression with the developmental or hormonal state of
the mammary gland: all reduction mammoplasty and
fibroadenoma samples were from premenopausal patients
whose menstrual status was unknown, whereas the normal
breast samples adjacent to tumours were predominantly from
postmenopausal patients. However, it would be interesting to
determine whether the expression of this receptor changes
according to the hormonal milieu of the breast. Although age
related changes in the expression of ERα have been reported
in normal mammary gland, where the proportion of ERα
positive cells increases with age,25 we saw no such changes in
either the proportion or degree of expression of ERβ when
glands from premenopausal and postmenopausal women
were compared.
Although it is well established that ERα is regulated by PR,
there have been conflicting reports regarding the relation
between ERβ and PR. In the endometrium, PR significantly
correlated with ERα, but not with ERβ.26 A study of human
prostate revealed a significant association between PR and
both ERα and ERβ, where it was concluded that both ER sub-
types could induce PR expression.27 In our present study, the
analysis of serial sections revealed that although ERβ and PR
expression could be seen in the same tissue sections, it was not
always in the same cells. Thus, it seems likely that there is an
association between ERβ and PR in the mammary gland.
In conclusion, ER subtypes have distinct distribution
patterns in the normal mammary gland. The widespread dis-
tribution of ERβ suggests it may be the dominant ER in the
mammary gland, where we propose it may be acting as a
natural suppressor of oestrogen activity.
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Take home messages
• Oestrogen receptor α (ERα) expression was restricted to
the cell nuclei of epithelial cells lining ducts and lobules
• ERβ was also expressed in these cells but additional
strong staining was seen in the cell nuclei of myoepithe-
lial cells and occasionally in surrounding stromal and
endothelial cell nuclei and in lymphocytes
• Thus, ER subtypes have distinct distribution patterns in
the normal mammary gland
• The widespread distribution of ERβ suggests that it may
be the dominant ER in the mammary gland, where it
may be acting as a natural suppressor
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